Comparative Pharmacology
Head-to-head clinical analysis: REVUFORJ versus RUXOLITINIB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: REVUFORJ versus RUXOLITINIB.
REVUFORJ vs Ruxolitinib
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
REVUFORJ (revumenib) is a potent and selective oral inhibitor of the menin-KMT2A (MLL) protein-protein interaction. It blocks the binding of menin to the N-terminus of KMT2A fusion proteins and mutant NPM1, thereby inhibiting the transcriptional activation of downstream target genes (e.g., HOXA9, MEIS1) that drive leukemogenesis.
Selective inhibitor of Janus-associated kinases (JAK) JAK1 and JAK2, reducing cytokine signaling and hematopoiesis.
Oral, 500 mg twice daily.
Myelofibrosis: 5-25 mg orally twice daily based on platelet count; Polycythemia Vera: 10 mg orally twice daily; Graft-versus-Host Disease: 5-10 mg orally twice daily.
None Documented
None Documented
Clinical Note
moderateRuxolitinib + Digoxin
"Ruxolitinib may increase the bradycardic activities of Digoxin."
Clinical Note
moderateRuxolitinib + Digitoxin
"Ruxolitinib may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateRuxolitinib + Deslanoside
"Ruxolitinib may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateRuxolitinib + Acetyldigitoxin
"Ruxolitinib may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 40 hours in healthy subjects; extended to 72 hours in patients with moderate hepatic impairment (Child-Pugh B), requiring dose adjustment.
The terminal elimination half-life of ruxolitinib is approximately 3 hours for the parent drug. However, the pharmacodynamic half-life for JAK2 inhibition is longer (up to 8-12 hours) due to sustained target suppression.
Primarily renal excretion of unchanged drug (approximately 70%) and fecal excretion (approximately 20%) via biliary elimination; minimal metabolism.
Ruxolitinib is primarily metabolized in the liver, and its metabolites are excreted renally. Approximately 74% of the dose is eliminated in urine (mainly as metabolites) and 22% in feces (as unchanged drug and metabolites).
Category C
Category D/X
JAK Inhibitor
JAK Inhibitor